Incyte Presents New Late-Breaking Data from Phase 2 Study Ev

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis...

Related Keywords

San Diego , California , United States , America , American , , American Academy Of Dermatology , Facebook , Linkedin , Instagram , Exchange Commission , Youtube , National Organization For Rare Disorders , Late Breaking Research , American Academy , Annual Meeting , Numerical Rating Scale , Global Assessment Treatment Success , North America , Accessed February , Markets ,